Skip to Content

Breast-Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus Trastuzumab

Objective

NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

To determine whether the addition of the drug trastuzumab (Herceptin) to chemotherapy improves invasive disease-free survival in women with resected node-positive or high-risk node negative breast cancer with reported HER-2 low by all HER 2 testing performed

Sponsor(s)
National Surgical Adjuvant Breast and Bowel Project, an NCI Cooperative Group
Contact
Rebecca Denofer, RN, OCN at 802-747-1692
or rdenofer@rrmc.org

Rutland Regional Medical Center
160 Allen Street
Rutland, VT 05701
802.775.7111

Facebook YouTube LinkedIn CarePages Twitter